N-Me-L-Ala-maytansinol, with the CAS number 77668-69-0, is a synthetic derivative of maytansine, a potent antitumor agent originally derived from the plant Maytenus serrata. This compound features a methylated amino acid (N-methyl-L-alanine) as part of its structure, which contributes to its biological activity. Characteristically, N-Me-L-Ala-maytansinol exhibits significant cytotoxic properties, making it of interest in cancer research and therapeutic applications. Its mechanism of action primarily involves the inhibition of microtubule dynamics, leading to cell cycle arrest and apoptosis in cancer cells. The compound is typically studied for its potential in targeted cancer therapies, particularly in the development of antibody-drug conjugates. Additionally, its stability, solubility, and pharmacokinetic properties are critical factors that influence its efficacy and safety profile in clinical settings. As with many antitumor agents, ongoing research aims to optimize its therapeutic index while minimizing adverse effects.

Maytansinoid-Ala is a potent microtubule-targeted compound that inhibits proliferation of cells at mitosis. Maytansinoid-Ala can be used for synthesis of ADCs. The microtubule-targeting maytansinoids accumulate in cells and induce mitotic arrest at 250- to 1000-fold lower concentrations than those required for their association with tubulin or microtubules.

N-Me-L-Ala-maytansinol

77668-69-0: N-Me-L-Ala-maytansinol, with the CAS number 77668-69-0, is a synthetic derivative of maytansine, a potent antitumor agent originally derived from the plant Maytenus serrata. This compound features a methylated amino acid (N-methyl-L-alanine) as part of its structure, which contributes to its biological activity. Characteristically, N-Me-L-Ala-maytansinol exhibits significant cytotoxic properties, making it of interest in cancer research and therapeutic applications. Its mechanism of action primarily involves the inhibition of microtubule dynamics, leading to cell cycle arrest and apoptosis in cancer cells. The compound is typically studied for its potential in targeted cancer therapies, particularly in the development of antibody-drug conjugates. Additionally, its stability, solubility, and pharmacokinetic properties are critical factors that influence its efficacy and safety profile in clinical settings. As with many antitumor agents, ongoing research aims to optimize its therapeutic index while minimizing adverse effects.

<p>N-Me-L-Ala-maytansinol used for making antibody-drug conjugate (ADC),is a hydrophobic, cell permeable payload.</p>

CAS 77668-69-0

N-Me-L-Ala-maytansinol

N-Me-L-Ala-maytansinol

Ref: TM-T12149